Testing ETHY-001 injections for safety in thyroid eye disease
Tests ETHY-001 given under the skin in healthy volunteers and people with thyroid eye disease.
Key facts
- Who runs it
- Ethyreal Bio, Inc.
- Where
- Las Vegas, Orland Park, and Wilmington, United StatesSee the 3 sites
- Trial code
- Registry title
- Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 72 people, planned
- Started
- 6 Jul 2026
- Expected to end
- 15 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- ETHY-001
- Placebo
- Record updated
- 26 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy volunteers (Part A) and people with thyroid eye disease (Part B). They will get one injection under the skin of ETHY-001 or a placebo (dummy drug).
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Part B only: moderate-to-severe thyroid eye disease (TED).
- Earlier treatment
- People who were ever treated with teprotumumab or other anti-IGF-1R monoclonal antibodies cannot join. No investigational drug within 60 days before the first study injection.
Main reasons for not taking part
- Serious medical conditions, active liver or kidney problems, or abnormal blood pressure or ECG at screening
- Known allergy to monoclonal antibody products or to injections under the skin
- Pregnancy, plans for pregnancy, or breastfeeding
- Alcohol or substance abuse in the 12 months before screening
- Past treatment with teprotumumab or other anti-IGF-1R monoclonal antibodies
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Parts A and B:
- Body mass index of 18 kg/m2 at screening
- Agree to comply with all protocol requirements
- Able to provide written informed consent
- Agree to defined medications and monitoring as instructed by the site; Other protocol-defined inclusion criteria will apply; Part B Only:
- Must meet the criteria for moderate-to-severe TED
Who cannot take part
- The participant has a history of alcohol or substance abuse within the last 12 months before screening
- Use of any investigational drug within 60 days prior to the first injection of study drug
- History of treatment with teprotumumab or other anti-IGF-1R monoclonal antibodies; Other protocol-defined exclusion criteria apply
- Significant medical conditions or physical findings that may affect participant safety
- Known hypersensitivity to monoclonal antibody products and/or subcutaneous injections
- Part A and Part B:
- Active liver or kidney dysfunction at screening
- Blood pressure or ECG abnormalities at screening
- Pregnancy of plans for pregnancy; breastfeeding
Where in United States
- Las Vegas, NevadaHospital not named in the registryContact: Ethyreal BioNo longer taking part
- Orland Park, IllinoisHospital not named in the registryContact: Ethyreal BioTaking people
- Wilmington, North CarolinaHospital not named in the registryContact: Ethyreal BioTaking people
About the trial
What the trial wants to find out
The primary objective of study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ETHY-001 in healthy volunteers and participants with Thyroid Eye Disease after single subcutaneous doses.
The 2 groups in the trial
- ETHY-001Treatment being tested
Participants in multiple cohorts will receive ETHY-001 in Single Ascending Doses (SAD).
- PlaceboPlacebo, for comparison
Participants in multiple cohorts will receive a placebo comparator.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-Masked, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ETHY-001
- Plain-language title
- Testing ETHY-001 injections for safety in thyroid eye diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 26 October 2026